Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, palonosetron (Aloxi®) cannot be endorsed for use within NHS Wales for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in paediatric patients 1 month of age and older. |
||
|
||
Medicine details |
||
| Medicine name | palonosetron (Aloxi®) | |
| Formulation | 250 micrograms solution for injection | |
| Reference number | 2613 | |
| Indication | For the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in paediatric patients 1 month of age and older. |
|
| Company | Helsinn Birex Pharmaceuticals Ltd | |
| BNF chapter | Central nervous system | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 26/06/2015 | |
| Date of issue | 30/06/2015 | |